यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
rexxolide
dechra regulatory b.v. - tulatromycín - antibakteriálne látky na systémové použitie - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. prítomnosť ochorenia v stáde by sa mala stanoviť pred metafylaktickou liečbou. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. prítomnosť ochorenia v stáde by sa mala stanoviť pred metafylaktickou liečbou. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovce: liečba skorých štádií infekčnej podkožne (zápal pažeráka) spojená s virulentným dichelobacter nodosus, ktorý si vyžaduje systémovú liečbu.
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
vaxzevria (previously covid-19 vaccine astrazeneca)
astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vakcíny - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.
यूरोपीय संघ -
स्लोवाक -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastické činidlá - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.